Solvency ratios also known as long-term debt ratios measure a company ability to meet long-term obligations.
Paying user area
Try for free
Cytokinetics Inc. pages available for free this week:
- Statement of Comprehensive Income
- Analysis of Liquidity Ratios
- Analysis of Short-term (Operating) Activity Ratios
- Enterprise Value to FCFF (EV/FCFF)
- Net Profit Margin since 2005
- Current Ratio since 2005
- Price to Book Value (P/BV) since 2005
- Price to Sales (P/S) since 2005
- Analysis of Revenues
- Analysis of Debt
The data is hidden behind: . Unhide it.
Get full access to the entire website from $10.42/mo, or
get 1-month access to Cytokinetics Inc. for $22.49.
This is a one-time payment. There is no automatic renewal.
We accept:
Solvency Ratios (Summary)
Based on: 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31).
The analysis of the financial ratios from the quarterly data reveals notable fluctuations and trends over the examined periods.
- Debt to Equity Ratio
- The debt to equity ratio starts at a high value of 12.63 and then shows an initial absence of data before reappearing at a significantly lower value of 0.9 by the end of 2020. Subsequently, it exhibits variability, peaking at 8.44 during late 2021, before stabilizing around values between 0.57 and 1.77 in early 2022. This indicates periods of increased leverage followed by relative deleveraging.
- Debt to Equity Ratio (Including Operating Lease Liability)
- This metric follows a similar trajectory as the standard debt to equity ratio but records slightly higher magnitudes, peaking notably at 14.98 in late 2021. This suggests that operating lease liabilities contribute a measurable portion to the company's overall leverage during peak periods.
- Debt to Capital Ratio
- This ratio displays considerable volatility across the quarters. It initially rises from 0.93 to 2.44 in mid-2020, then declines to a low of 0.36 by late 2021, before increasing again to 3.58 by late 2023. The pattern indicates alternating periods of increased and decreased reliance on debt financing relative to total capital.
- Debt to Capital Ratio (Including Operating Lease Liability)
- Accounting for operating lease liabilities, this ratio mirrors the standard debt to capital ratio but remains consistently higher. The peaks and troughs align closely, confirming the significance of lease obligations in the capital structure dynamics.
- Debt to Assets Ratio
- The debt to assets ratio shows growth over time, starting from 0.21 and progressing to 0.82 by late 2023. There is a general trend of increasing debt relative to the company's asset base, with some fluctuations during the intermediate quarters.
- Debt to Assets Ratio (Including Operating Lease Liability)
- Similar to the previous metric, this ratio increases over the period, rising from 0.26 to 1.01. The inclusion of operating lease liabilities maintains a higher level throughout, emphasizing their impact on the company's leverage relative to assets.
- Financial Leverage
- Financial leverage data is limited but demonstrates a sharp decrease from 58.9 initially to values around 3 to 8 between 2020 and 2021, and then further variability without data in the latter periods. The initial high value may reflect reporting or calculation anomalies or an exceptional leverage event.
- Interest Coverage Ratio
- This ratio remains consistently negative throughout the timeline, ranging from -24.68 to approximately -6.77 in early 2020, and then worsening again to around -17 in 2023. Negative interest coverage indicates that the company is not generating sufficient earnings before interest and taxes to cover interest expenses, which points to operational challenges in profitability or high interest burdens.
Overall, the company exhibits fluctuating debt levels relative to equity, capital, and assets, with occasional periods of increased leverage. The persistent negative interest coverage reflects ongoing difficulties in meeting interest obligations from earnings. Operating lease liabilities significantly affect the debt-related ratios, highlighting their importance in assessing the overall leverage profile. The trends indicate a careful evaluation of the company’s capital structure and operational efficiency is warranted to understand the underlying drivers and sustainability of these financial positions.
Debt Ratios
Coverage Ratios
Debt to Equity
| Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in thousands) | |||||||||||||||||||||||||
| Current portion of long-term debt | |||||||||||||||||||||||||
| Term loan, net, excluding current portion | |||||||||||||||||||||||||
| Convertible notes, net | |||||||||||||||||||||||||
| Total debt | |||||||||||||||||||||||||
| Stockholders’ equity (deficit) | |||||||||||||||||||||||||
| Solvency Ratio | |||||||||||||||||||||||||
| Debt to equity1 | |||||||||||||||||||||||||
| Benchmarks | |||||||||||||||||||||||||
| Debt to Equity, Competitors2 | |||||||||||||||||||||||||
| AbbVie Inc. | |||||||||||||||||||||||||
| Amgen Inc. | |||||||||||||||||||||||||
| Bristol-Myers Squibb Co. | |||||||||||||||||||||||||
| Danaher Corp. | |||||||||||||||||||||||||
| Eli Lilly & Co. | |||||||||||||||||||||||||
| Gilead Sciences Inc. | |||||||||||||||||||||||||
| Johnson & Johnson | |||||||||||||||||||||||||
| Merck & Co. Inc. | |||||||||||||||||||||||||
| Pfizer Inc. | |||||||||||||||||||||||||
| Regeneron Pharmaceuticals Inc. | |||||||||||||||||||||||||
| Thermo Fisher Scientific Inc. | |||||||||||||||||||||||||
| Vertex Pharmaceuticals Inc. | |||||||||||||||||||||||||
Based on: 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31).
1 Q3 2023 Calculation
Debt to equity = Total debt ÷ Stockholders’ equity (deficit)
= ÷ =
2 Click competitor name to see calculations.
The financial data reveals several notable trends regarding the company’s capital structure and financial stability over the observed periods.
- Total Debt
- Total debt increased substantially from the first quarter of 2019 through to late 2020, rising from approximately $42.6 million to around $136 million by December 2020. From early 2021 to mid-2022, total debt increased more gradually, reaching close to $197 million. A significant jump occurred from the third quarter of 2022, with debt levels rising dramatically to over $600 million by early 2023, remaining relatively stable thereafter.
- Stockholders’ Equity (Deficit)
- Stockholders’ equity showed considerable volatility. Initially positive in early 2019, equity turned negative by mid-2019 and fluctuated with some recovery in late 2020 and 2021 reaching as high as nearly $250 million. However, starting in late 2021 and through 2022, equity moved back into deficit territory and continued to decline sharply in 2023, reaching an increasingly negative position near -$439 million by the third quarter of 2023.
- Debt to Equity Ratio
- The debt to equity ratio exhibited marked fluctuations, reflective of the interplay between rising debt and variable equity levels. Early ratios were elevated, with extremes noted around 2019 when the ratio exceeded 12.6, indicating very high leverage. During late 2020 and through 2021, this ratio stabilized to a range between 0.57 and 2.02. However, data for later periods is incomplete. Overall, the prior data points suggest periods of both moderate and high financial leverage, correlating with the volatility observed in equity.
In summary, the company has experienced a trend of increasing total debt, particularly pronounced from late 2022 onward. Stockholders’ equity has been volatile, transitioning from positive to significant negative values, indicating potential concerns over net asset value. The debt to equity ratio’s fluctuations mirror these changes and imply shifts in financial risk and capital structure management over time. The recent substantial rise in debt alongside increasingly negative equity positions suggests a heightened financial leverage risk as of the latest periods analyzed.
Debt to Equity (including Operating Lease Liability)
Cytokinetics Inc., debt to equity (including operating lease liability) calculation (quarterly data)
| Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in thousands) | |||||||||||||||||||||||||
| Current portion of long-term debt | |||||||||||||||||||||||||
| Term loan, net, excluding current portion | |||||||||||||||||||||||||
| Convertible notes, net | |||||||||||||||||||||||||
| Total debt | |||||||||||||||||||||||||
| Short-term operating lease liabilities | |||||||||||||||||||||||||
| Long-term operating lease liabilities | |||||||||||||||||||||||||
| Total debt (including operating lease liability) | |||||||||||||||||||||||||
| Stockholders’ equity (deficit) | |||||||||||||||||||||||||
| Solvency Ratio | |||||||||||||||||||||||||
| Debt to equity (including operating lease liability)1 | |||||||||||||||||||||||||
| Benchmarks | |||||||||||||||||||||||||
| Debt to Equity (including Operating Lease Liability), Competitors2 | |||||||||||||||||||||||||
| Vertex Pharmaceuticals Inc. | |||||||||||||||||||||||||
Based on: 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31).
1 Q3 2023 Calculation
Debt to equity (including operating lease liability) = Total debt (including operating lease liability) ÷ Stockholders’ equity (deficit)
= ÷ =
2 Click competitor name to see calculations.
- Total Debt (including operating lease liability)
- The total debt level remained relatively stable from early 2019 through mid-2020, fluctuating around $52 million to $138 million (in thousands). A significant increase began in early 2021, with debt rising from approximately $228 million in March 2021 to over $749 million by mid-2023. This suggests a substantial increase in the company's leverage or financing activities over this period.
- Stockholders’ Equity (Deficit)
- Stockholders’ equity exhibited considerable volatility across the periods observed. Initially positive at $3.4 million in March 2019, it turned negative by June 2019 and remained negative through 2020 with a notable positive spike to approximately $149.6 million in September 2020. After this peak, equity fluctuated with significant swings and overall negative trends emerging again in late 2022 and continuing worsening through mid-2023, reaching a deficit exceeding $438 million. This pattern indicates unstable equity position with periods of recovery followed by marked declines.
- Debt to Equity Ratio (Including Operating Lease Liability)
- The debt-to-equity ratio metrics are incomplete, but available data show dramatic variations. The ratio was extremely high at 15.53 in March 2019, declined to a low of 0.93 to 1.23 between mid to late 2020, then sharply increased again to as high as 14.98 by June 2021. Subsequent values of 1.05, 1.11, 2.77, and 2.91 between late 2021 and early 2022 demonstrate ongoing instability in the company's financing leverage relative to equity. The missing data post early 2022 precludes further assessment, but the observed values emphasize high leverage variability and financial structure shifts.
- Overall Financial Trends
- The financial data reflect a company experiencing significant changes in its capital structure over the analyzed periods. The surge in total debt starting in 2021, combined with the persistent and deepening negative stockholders’ equity in later periods, indicates increasing reliance on debt financing amid deteriorating equity value. Fluctuating and generally high debt-to-equity ratios reinforce the observation of heightened leverage and potential financial risk. These patterns point to a potentially stressed equity base offset by growing debt commitments.
Debt to Capital
| Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in thousands) | |||||||||||||||||||||||||
| Current portion of long-term debt | |||||||||||||||||||||||||
| Term loan, net, excluding current portion | |||||||||||||||||||||||||
| Convertible notes, net | |||||||||||||||||||||||||
| Total debt | |||||||||||||||||||||||||
| Stockholders’ equity (deficit) | |||||||||||||||||||||||||
| Total capital | |||||||||||||||||||||||||
| Solvency Ratio | |||||||||||||||||||||||||
| Debt to capital1 | |||||||||||||||||||||||||
| Benchmarks | |||||||||||||||||||||||||
| Debt to Capital, Competitors2 | |||||||||||||||||||||||||
| AbbVie Inc. | |||||||||||||||||||||||||
| Amgen Inc. | |||||||||||||||||||||||||
| Bristol-Myers Squibb Co. | |||||||||||||||||||||||||
| Danaher Corp. | |||||||||||||||||||||||||
| Eli Lilly & Co. | |||||||||||||||||||||||||
| Gilead Sciences Inc. | |||||||||||||||||||||||||
| Johnson & Johnson | |||||||||||||||||||||||||
| Merck & Co. Inc. | |||||||||||||||||||||||||
| Pfizer Inc. | |||||||||||||||||||||||||
| Regeneron Pharmaceuticals Inc. | |||||||||||||||||||||||||
| Thermo Fisher Scientific Inc. | |||||||||||||||||||||||||
| Vertex Pharmaceuticals Inc. | |||||||||||||||||||||||||
Based on: 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31).
1 Q3 2023 Calculation
Debt to capital = Total debt ÷ Total capital
= ÷ =
2 Click competitor name to see calculations.
The analysis of the quarterly financial data reveals significant fluctuations and trends in the company's debt and capital structure over the observed periods.
- Total Debt
-
Total debt shows a general increasing trend throughout the timeline. Starting from approximately $42.6 million in early 2019, debt rose steadily with occasional sharper increases, notably large jumps in early 2022 and still high levels sustained through 2023 near $610 million. This indicates increased leverage or financing activities over time, with a substantial escalation beginning in 2022.
- Total Capital
-
Total capital exhibits a more volatile pattern with considerable variation quarter-to-quarter. Initial values fluctuate widely early on, with a peak near $388 million in late 2021, followed by a pronounced decline into 2023 reaching levels below $200 million. The capital shows no consistent upward or downward linear trend but rather reflects substantial changes, possibly due to capital raising or asset revaluation events.
- Debt to Capital Ratio
-
The debt to capital ratio experiences considerable volatility, starting from a ratio under 1 in early 2019, peaking at 1.8 towards the end of 2019, and then showing varied oscillations especially through 2020 and 2021 with ratios ranging from 0.36 to near 0.9. From early 2022 onwards, the ratio consistently increases, surpassing 1 in early 2022 and reaching a very high level of 3.58 by the third quarter of 2023. This sharp rise indicates a growing reliance on debt relative to capital, signaling increased financial leverage and potentially higher risk.
Overall, while total debt has grown significantly over the analyzed period, total capital has been more erratic with substantial fluctuations. The escalating debt to capital ratio in recent periods suggests that the company has increasingly financed its operations through debt, which may have implications for its financial stability and risk profile going forward.
Debt to Capital (including Operating Lease Liability)
Cytokinetics Inc., debt to capital (including operating lease liability) calculation (quarterly data)
| Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in thousands) | |||||||||||||||||||||||||
| Current portion of long-term debt | |||||||||||||||||||||||||
| Term loan, net, excluding current portion | |||||||||||||||||||||||||
| Convertible notes, net | |||||||||||||||||||||||||
| Total debt | |||||||||||||||||||||||||
| Short-term operating lease liabilities | |||||||||||||||||||||||||
| Long-term operating lease liabilities | |||||||||||||||||||||||||
| Total debt (including operating lease liability) | |||||||||||||||||||||||||
| Stockholders’ equity (deficit) | |||||||||||||||||||||||||
| Total capital (including operating lease liability) | |||||||||||||||||||||||||
| Solvency Ratio | |||||||||||||||||||||||||
| Debt to capital (including operating lease liability)1 | |||||||||||||||||||||||||
| Benchmarks | |||||||||||||||||||||||||
| Debt to Capital (including Operating Lease Liability), Competitors2 | |||||||||||||||||||||||||
| Vertex Pharmaceuticals Inc. | |||||||||||||||||||||||||
Based on: 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31).
1 Q3 2023 Calculation
Debt to capital (including operating lease liability) = Total debt (including operating lease liability) ÷ Total capital (including operating lease liability)
= ÷ =
2 Click competitor name to see calculations.
The analysis of the quarterly financial data reveals several notable trends and fluctuations in the company's leverage and capital structure over the examined periods.
- Total Debt (Including Operating Lease Liability)
- The total debt level displays a general increasing trend, starting from approximately $52.4 million in early 2019 and rising significantly to about $748.5 million by the third quarter of 2023. There are marked jumps in debt in certain periods, especially from late 2021 through 2022 and into 2023, indicating substantial borrowing or lease obligations. The debt level increased notably between December 2021 and September 2022, moving from around $270 million to nearly $739 million, which is a substantial rise within a year.
- Total Capital (Including Operating Lease Liability)
- Total capital figures exhibit high volatility and do not follow a consistent upward or downward path. Starting at roughly $55.7 million at the beginning of 2019, total capital sharply decreases by September 2019, reaching a low around $32.7 million. Following that, fluctuations occur, including a notable peak near $509.9 million in late 2021, which suggests capital injections or revaluations during this time. Subsequently, capital declines steadily through 2022 and 2023, falling to approximately $309.7 million by the third quarter of 2023. These fluctuations highlight considerable variability in capital structure, with periods of both contraction and expansion.
- Debt to Capital Ratio
- The debt to capital ratio shows significant volatility and tends to increase overall throughout the period. Initially, the ratio begins below 1.0 in early 2019 but rises dramatically above 1.6 in the third quarter of that year, reflecting debt exceeding total capital. The ratio decreases to around 0.48 to 0.55 in late 2020, indicating a relative reduction in leverage during that period. However, from 2021 onwards, the ratio steadily climbs, surpassing 1.0 again in late 2022 and reaching a peak of 2.42 by the third quarter of 2023. This level indicates that debt is more than double the total capital, signaling a high leverage position and increased financial risk.
Overall, the data point to a company progressively increasing its debt burden relative to its capital base, with substantial variability in capital amounts. This pattern could indicate aggressive financing strategies, possibly to fund growth or operational needs, but it also implies rising financial leverage and potential vulnerability to credit and market conditions.
Debt to Assets
| Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in thousands) | |||||||||||||||||||||||||
| Current portion of long-term debt | |||||||||||||||||||||||||
| Term loan, net, excluding current portion | |||||||||||||||||||||||||
| Convertible notes, net | |||||||||||||||||||||||||
| Total debt | |||||||||||||||||||||||||
| Total assets | |||||||||||||||||||||||||
| Solvency Ratio | |||||||||||||||||||||||||
| Debt to assets1 | |||||||||||||||||||||||||
| Benchmarks | |||||||||||||||||||||||||
| Debt to Assets, Competitors2 | |||||||||||||||||||||||||
| AbbVie Inc. | |||||||||||||||||||||||||
| Amgen Inc. | |||||||||||||||||||||||||
| Bristol-Myers Squibb Co. | |||||||||||||||||||||||||
| Danaher Corp. | |||||||||||||||||||||||||
| Eli Lilly & Co. | |||||||||||||||||||||||||
| Gilead Sciences Inc. | |||||||||||||||||||||||||
| Johnson & Johnson | |||||||||||||||||||||||||
| Merck & Co. Inc. | |||||||||||||||||||||||||
| Pfizer Inc. | |||||||||||||||||||||||||
| Regeneron Pharmaceuticals Inc. | |||||||||||||||||||||||||
| Thermo Fisher Scientific Inc. | |||||||||||||||||||||||||
| Vertex Pharmaceuticals Inc. | |||||||||||||||||||||||||
Based on: 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31).
1 Q3 2023 Calculation
Debt to assets = Total debt ÷ Total assets
= ÷ =
2 Click competitor name to see calculations.
- Total Debt
- The total debt exhibited a gradual increase from approximately $42.6 million at the end of March 2019 to around $143 million by December 2021. A significant surge occurred between June and September 2022, with debt rising sharply from roughly $197 million to over $608 million, after which it remained relatively stable, fluctuating slightly around $609 million through the third quarter of 2023.
- Total Assets
- Total assets showed some volatility over the period, starting near $199 million in early 2019 and rising to a peak of approximately $841 million by December 2021. Thereafter, assets initially continued to increase, reaching a high near $1.08 billion in September 2022, before declining steadily to about $741 million by September 2023.
- Debt to Assets Ratio
- The debt to assets ratio followed a fluctuating but overall upward trend. It began at 0.21 in March 2019 and climbed to nearly 0.45 by December 2019, reflecting increasing leverage. The ratio then dipped to a low of around 0.17 in late 2021, corresponding with the asset increase outpacing debt growth. However, from early 2022 onwards, the ratio rose sharply again, reaching 0.82 by September 2023, indicating a substantial increase in leverage driven by a pronounced increase in total debt relative to assets.
- Overall Insights
- The data indicate a strategic increase in borrowing commencing around mid-2022, significantly elevating the company's financial leverage. Despite the growth in total assets up to late 2022, the rate of asset increase was outpaced by the rise in debt subsequently. The rising debt to assets ratio approaching 0.82 by late 2023 suggests a higher risk profile due to increased indebtedness relative to asset base. This pattern may require monitoring to assess the company's capacity to manage and service its debt moving forward.
Debt to Assets (including Operating Lease Liability)
Cytokinetics Inc., debt to assets (including operating lease liability) calculation (quarterly data)
| Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in thousands) | |||||||||||||||||||||||||
| Current portion of long-term debt | |||||||||||||||||||||||||
| Term loan, net, excluding current portion | |||||||||||||||||||||||||
| Convertible notes, net | |||||||||||||||||||||||||
| Total debt | |||||||||||||||||||||||||
| Short-term operating lease liabilities | |||||||||||||||||||||||||
| Long-term operating lease liabilities | |||||||||||||||||||||||||
| Total debt (including operating lease liability) | |||||||||||||||||||||||||
| Total assets | |||||||||||||||||||||||||
| Solvency Ratio | |||||||||||||||||||||||||
| Debt to assets (including operating lease liability)1 | |||||||||||||||||||||||||
| Benchmarks | |||||||||||||||||||||||||
| Debt to Assets (including Operating Lease Liability), Competitors2 | |||||||||||||||||||||||||
| Vertex Pharmaceuticals Inc. | |||||||||||||||||||||||||
Based on: 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31).
1 Q3 2023 Calculation
Debt to assets (including operating lease liability) = Total debt (including operating lease liability) ÷ Total assets
= ÷ =
2 Click competitor name to see calculations.
The financial analysis of the quarterly data reveals several significant trends related to total debt, total assets, and the debt-to-assets ratio over the examined period.
- Total Debt
- Total debt, inclusive of operating lease liabilities, demonstrated a relatively stable level during the initial quarters from March 2019 through September 2019, fluctuating slightly around the range of approximately $52 million to $53 million. However, a marked increase occurred at the end of 2019, with debt nearly tripling to around $136 million by December 31, 2019. This elevated level of debt persisted with minor incremental increases through 2020.
- In 2021 and early 2022, total debt escalated further, surpassing $320 million by March 2022 and reaching an exceptionally high value of approximately $739 million in September 2022. After this peak, total debt remained relatively stable at around $748 million through the first three quarters of 2023.
- Total Assets
- Total assets displayed fluctuating trends with distinct periods of growth and decline. Initially, from March 2019 to December 2019, assets rose substantially from roughly $199 million to about $290 million. Following this, assets experienced volatility with a notable large increase at the end of 2020 and into 2021, peaking at over $841 million by December 2021.
- However, from early 2022 onward, total assets saw a degree of fluctuation with a decline after March 2022, followed by a recovery peak at nearly $1.08 billion in December 2022. Subsequently, there was a downward trajectory through 2023, with assets decreasing to approximately $741 million by September 2023.
- Debt to Assets Ratio
- The debt-to-assets ratio illustrates the relationship between debt and total assets and points to changes in financial leverage. Initially, this ratio remained moderate, starting around 0.26 in March 2019 and rising incrementally to 0.47 by December 2019, reflecting the surge in debt relative to assets during that time.
- Throughout 2020, the ratio varied significantly, peaking at 0.59 mid-year, then declining to the low 0.20s by the end of the year, indicating a substantial change in the balance between debt and assets.
- From 2021 through early 2022, the ratio fluctuated around the 0.30 to 0.40 range but then increased steeply starting in mid-2022, reaching 0.69 by December 2022 and climbing sharply to above 1.00 by September 2023. This level suggests that total debt slightly exceeded total assets by the latest quarter, indicating high financial leverage and potentially elevated financial risk.
Overall, the analysis identifies a general pattern of increasing leverage over the period, primarily driven by significant growth in total debt that outpaced asset growth in the most recent periods. The rising debt-to-assets ratio to levels above unity warrants close monitoring, as it indicates a reliance on debt financing that exceeds the asset base, potentially impacting the company's financial stability.
Financial Leverage
| Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in thousands) | |||||||||||||||||||||||||
| Total assets | |||||||||||||||||||||||||
| Stockholders’ equity (deficit) | |||||||||||||||||||||||||
| Solvency Ratio | |||||||||||||||||||||||||
| Financial leverage1 | |||||||||||||||||||||||||
| Benchmarks | |||||||||||||||||||||||||
| Financial Leverage, Competitors2 | |||||||||||||||||||||||||
| AbbVie Inc. | |||||||||||||||||||||||||
| Amgen Inc. | |||||||||||||||||||||||||
| Bristol-Myers Squibb Co. | |||||||||||||||||||||||||
| Danaher Corp. | |||||||||||||||||||||||||
| Eli Lilly & Co. | |||||||||||||||||||||||||
| Gilead Sciences Inc. | |||||||||||||||||||||||||
| Johnson & Johnson | |||||||||||||||||||||||||
| Merck & Co. Inc. | |||||||||||||||||||||||||
| Pfizer Inc. | |||||||||||||||||||||||||
| Regeneron Pharmaceuticals Inc. | |||||||||||||||||||||||||
| Thermo Fisher Scientific Inc. | |||||||||||||||||||||||||
| Vertex Pharmaceuticals Inc. | |||||||||||||||||||||||||
Based on: 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31).
1 Q3 2023 Calculation
Financial leverage = Total assets ÷ Stockholders’ equity (deficit)
= ÷ =
2 Click competitor name to see calculations.
The analysis of the quarterly financial data reveals several noteworthy trends over the examined periods.
- Total Assets
- The total assets of the company exhibit variability with an overall upward trajectory from March 2019 through September 2023. Starting at approximately 198.6 million USD in March 2019, there is a noticeable dip around mid-2019, followed by a significant increase peaking around the fourth quarter of 2022 at approximately 1.08 billion USD. After this peak, a declining trend is observed, with assets decreasing to approximately 740.6 million USD by September 2023. This pattern suggests phases of asset growth, possibly due to acquisitions, capital investments, or financing activities, followed by partial asset reduction or reorganization in more recent quarters.
- Stockholders’ Equity (Deficit)
- The stockholders’ equity displays considerable volatility with periods of both deficit and positive equity. Initially, equity is positive but relatively low—approximately 3.4 million USD at March 2019—soon shifting to negative territory during mid to late 2019 and early 2020, reaching a deficit of roughly -78.1 million USD by June 2020. Subsequently, equity turned sharply positive in late 2020 and throughout 2021, peaking at approximately 249 million USD by September 2021. However, from late 2021 onwards, equity declined and moved back into deficit territory, with the largest negative equity reported as -438.8 million USD in September 2023. These fluctuations may reflect changes in retained earnings, share issuance or buybacks, comprehensive income variations, or reclassifications impacting equity.
- Financial Leverage
- The reported financial leverage ratio shows substantial fluctuations. Only select quarters provide leverage data, yet significant changes are observable. For example, leverage is low at 3.17 in late 2020, rising to a peak of 34.22 in the third quarter of 2021, indicating a sharp increase in the proportion of debt relative to equity during that period. Following that, leverage reduces again to values around 3.32 to 7.36 in the subsequent quarters. This variability in leverage points to periods of increased reliance on debt financing or shifts in equity balances, potentially linked to the movements in stockholders’ equity noted earlier.
Overall, the financial data points to a company undergoing significant changes in its capital structure and asset base. The substantial swings in equity from deficit to surplus and back, alongside fluctuating total assets and financial leverage, indicate dynamic financial management, possibly including debt restructuring, capital raises or reductions, and asset reallocation. The recent trend toward diminishing total assets and increasing equity deficits may warrant attention to sustainability and solvency considerations.
Interest Coverage
| Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in thousands) | |||||||||||||||||||||||||
| Net loss | |||||||||||||||||||||||||
| Add: Income tax expense | |||||||||||||||||||||||||
| Add: Interest expense | |||||||||||||||||||||||||
| Earnings before interest and tax (EBIT) | |||||||||||||||||||||||||
| Solvency Ratio | |||||||||||||||||||||||||
| Interest coverage1 | |||||||||||||||||||||||||
| Benchmarks | |||||||||||||||||||||||||
| Interest Coverage, Competitors2 | |||||||||||||||||||||||||
| Amgen Inc. | |||||||||||||||||||||||||
| Danaher Corp. | |||||||||||||||||||||||||
| Gilead Sciences Inc. | |||||||||||||||||||||||||
| Johnson & Johnson | |||||||||||||||||||||||||
| Regeneron Pharmaceuticals Inc. | |||||||||||||||||||||||||
| Thermo Fisher Scientific Inc. | |||||||||||||||||||||||||
| Vertex Pharmaceuticals Inc. | |||||||||||||||||||||||||
Based on: 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31).
1 Q3 2023 Calculation
Interest coverage
= (EBITQ3 2023
+ EBITQ2 2023
+ EBITQ1 2023
+ EBITQ4 2022)
÷ (Interest expenseQ3 2023
+ Interest expenseQ2 2023
+ Interest expenseQ1 2023
+ Interest expenseQ4 2022)
= ( + + + )
÷ ( + + + )
=
2 Click competitor name to see calculations.
- Earnings Before Interest and Tax (EBIT)
- Across the analyzed periods, the EBIT values reflect consistent negative figures, indicating persistent operating losses. The losses remain sizeable throughout, with some fluctuations. Initially, from early 2019 through mid-2020, the EBIT values range approximately between -28,000 to -37,000 thousand US dollars with one notable positive anomaly near September 2020 (801 thousand US dollars), which appears as an outlier. After this point, the losses deepen substantially, particularly towards the end of 2022 and early 2023, where EBIT values hover around -130,000 to -135,000 thousand US dollars. This trajectory suggests a worsening profitability position over the reported timeframe.
- Interest Expense
- The interest expense shows a gradual upward trend from early 2019 through 2023. Starting at approximately 1,170 thousand US dollars in the first quarter of 2019, it rises steadily over the years, reaching around 7,000 thousand US dollars by 2023. This consistent increase may reflect either higher debt levels or rising costs of borrowing. There are no dramatic fluctuations, indicating a stable but steadily increasing interest burden.
- Interest Coverage Ratio
- The interest coverage ratio, which measures the ability to meet interest payments from EBIT, remains consistently negative throughout the periods. The ratio starts from around -24.68 in early 2019 and shows some improvement towards the middle of 2020 (less negative values near -6.77), likely due to the temporary positive EBIT in that quarter. However, this improvement is short-lived as the ratio deteriorates again, reaching approximately -19 in early 2023. The negative values confirm that EBIT is insufficient to cover interest expenses, with the company's operating results unable to meet financial costs across all reported periods. The worsening coverage ratio alongside increased interest expenses highlights a stressed financial position in terms of debt servicing.